Retroperitoneal Carcinoma — Trials

Retroperitoneal Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

89 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 16
Ph III recruiting: 0
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (12)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02867592	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	active not recruiting	Phase 2	109	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT03333616	Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors	active not recruiting	Phase 2	100	Dana-Farber Cancer InstituteOTHER	1	Jul 23, 2026